Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Eli Lilly Moves First in India, Beats Novo in Obesity Drug Showdown

Daniel Kim Views  

Medical Today
Medical Today

Eli Lilly has launched its obesity treatment, Mounjaro, in India, making a significant play in one of the world’s largest pharmaceutical markets.

The company confirmed the rollout of Mounjaro—a GLP-1-based obesity medication—in India earlier this week. This strategic move positions Eli Lilly ahead of its primary competitor, Novo Nordisk, maker of the popular weight-loss drug Wegovy, in accessing India’s massive market of approximately 1.4 billion people.

After receiving approval from India’s drug regulatory authorities, Mounjaro will be administered as a once-weekly injection. Pricing in India is set at 4,375 rupees ($50.67) for a 5mg dose vial and 3,500 rupees ($40.54) for a 2.5mg vial. For patients receiving a standard weekly dose of 5mg, that equates to roughly $200 monthly.

Mounjaro’s active ingredient, tirzepatide, belongs to a class of medications known as GLP-1 receptor agonists—the same class as Wegovy. Tirzepatide is marketed under the Mounjaro brand in the U.K. and Europe for diabetes and obesity treatment. In the U.S., Eli Lilly sells Zepbound specifically for obesity treatment.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Why Your Eyelid Keeps Twitching—and When to Worry
  • Silent Spreaders: How Measles Can Infect Before Symptoms Appear
  • Eat More Eggplant—It’s Good for Your Blood and Your Heart
  • Want to Burn More Fat? Try a 30-Second Cold Shower, Experts Say
  • Bats, Fruit, and a Deadly Virus—Why Korea’s Health Officials Are on High Alert
  • Why You Crave Junk Food When You’re Sad—And What to Eat Instead

You May Also Like

  • 1
    Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa

    LATEST 

  • 2
    Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!

    LATEST 

  • 3
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 4
    COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?

    LATEST 

  • 5
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

Popular Now

  • 1
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 2
    Hydroleap Secures $4.75 Million to Revolutionize Water Treatment in Asia!

    LATEST 

  • 3
    Enhypen's New Single 'Yoi' Soars to the Top, Selling Over 300,000 Copies on Day One!

    LATEST 

  • 4
    Chanyeol of EXO Set to Drop Solo Album This August – Here’s What We Know!

    LATEST 

  • 5
    Caught Between Borders: Texas Man's Harrowing Eight-Day Detention

    LATEST 

Must-Reads

  • 1
    Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa

    LATEST 

  • 2
    Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!

    LATEST 

  • 3
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 4
    COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?

    LATEST 

  • 5
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

Popular Now

  • 1
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 2
    Hydroleap Secures $4.75 Million to Revolutionize Water Treatment in Asia!

    LATEST 

  • 3
    Enhypen's New Single 'Yoi' Soars to the Top, Selling Over 300,000 Copies on Day One!

    LATEST 

  • 4
    Chanyeol of EXO Set to Drop Solo Album This August – Here’s What We Know!

    LATEST 

  • 5
    Caught Between Borders: Texas Man's Harrowing Eight-Day Detention

    LATEST 

Share it on...